🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT07039903
Starting soon Not applicable

A Novel Psychological Intervention for Adults With Bipolar Disorder and Attention Deficit Hyperactivity Disorder Comorbidity (VECTOR)

NCT07039903 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2025-06-26

Condition(s) studied

ADHDBD

Investigational drug(s) / intervention(s)

Cognitive behavioral therapy (CBT) + Functional Remediation (FR)

Cognitive behavioral therapy (CBT) + Functional Remediation (FR): VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).

Study summary

Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Nevertheless, there is a paucity of research dedicated to the characterization and treatment of comorbid BD-ADHD.

This study aims to develop and evaluate the effectiveness of a novel psychological group intervention (VECTOR) for adults with BD-ADHD. VECTOR integrates elements from Cognitive Behavioral Therapy (CBT) for ADHD and Functional Remediation (FR) for BD.

Eighty patients will be randomized (1:1) to receive either the VECTOR program (12 weekly group sessions) or treatment as usual (TAU).

It is expected that the VECTOR program will result in greater improvements in functioning and symptom reduction compared to TAU.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Fulfill DSM-5 criteria for BDI or BDII and ADHD using the Structured Clinical Interview for DSM-5 and the Conners' Adult ADHD Diagnostic Interview (CAARS) * Aged ≥18 * Stable pharmacological treatment for at least the past three months. * Being in full or partial remission Young Mania Rating Scale (YMRS) ≤ 10, Hamilton Depression Rating Scale (HDRS) ≤ 14) at the time of the inclusion and assessment * ADHD rating scale≥24 Exclusion Criteria: * Any comorbid psychiatric condition * Diagnosis of substance abuse disorder in the past 12 months * Intellectual disability (intelligence quotient \< 70) * Having any Central Nervous System illness, independent of primary psychiatric diagnosis, hampering neuropsychological performance * Participation in a structured psychological intervention during the study period.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital Clínic de Barcelona and Vall d'Hebron University Hospital Barcelona Barcelona

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07039903 on ClinicalTrials.gov ↗ ← All trials in Spain